First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) ...
As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. Alongside a clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results